Praxis Precision Medicines, Inc. PRAX
We take great care to ensure that the data presented and summarized in this overview for Praxis Precision Medicines, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRAX
View allLatest Institutional Activity in PRAX
Top Purchases
Top Sells
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Insider Transactions at PRAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2024
|
Lauren Mastrocola Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
294
+4.74%
|
$10,878
$37.4 P/Share
|
|
Nov 14
2024
|
Timothy Edwin Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
205
+1.63%
|
$7,585
$37.4 P/Share
|
|
Nov 14
2024
|
Lauren Mastrocola Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,188
-48.04%
|
$420,228
$81.78 P/Share
|
|
Nov 14
2024
|
Lauren Mastrocola Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,374
+28.82%
|
$244,944
$56.94 P/Share
|
|
Nov 14
2024
|
Alex Nemiroff General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
8,239
-44.44%
|
$659,120
$80.2 P/Share
|
|
Nov 14
2024
|
Alex Nemiroff General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,583
+29.03%
|
$424,648
$56.94 P/Share
|
|
Jul 29
2024
|
Timothy Edwin Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+39.12%
|
-
|
|
Jul 29
2024
|
Lauren Mastrocola Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+41.18%
|
-
|
|
Jul 29
2024
|
Alex Nemiroff General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+41.58%
|
-
|
|
May 14
2024
|
Marcio Souza Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,718
+9.23%
|
$20,616
$12.37 P/Share
|
|
May 14
2024
|
Timothy Edwin Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
606
+12.25%
|
$7,272
$12.37 P/Share
|
|
Feb 12
2024
|
Marcio Souza Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
271
-1.75%
|
$11,924
$44.65 P/Share
|
|
Feb 12
2024
|
Alex Nemiroff General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
51
-1.59%
|
$2,244
$44.65 P/Share
|
|
Feb 12
2024
|
Lauren Mastrocola Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
48
-2.43%
|
$2,112
$44.65 P/Share
|
|
Jan 07
2024
|
Marcio Souza Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
418
-2.63%
|
$10,450
$25.19 P/Share
|
|
Jan 07
2024
|
Alex Nemiroff General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
89
-2.7%
|
$2,225
$25.19 P/Share
|
|
Jan 07
2024
|
Timothy Edwin Kelly Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
139
-3.59%
|
$3,475
$25.19 P/Share
|
|
Jan 07
2024
|
Lauren Mastrocola Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35
-1.74%
|
$875
$25.19 P/Share
|
|
Oct 05
2023
|
Jill De Simone Director |
BUY
Open market or private purchase
|
Direct |
14,500
+50.0%
|
$14,500
$1.75 P/Share
|
|
Jun 27
2023
|
Marcio Souza Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+18.18%
|
$10,000
$1.06 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 22.9K shares |
|---|---|
| Exercise of conversion of derivative security | 12K shares |
| Payment of exercise price or tax liability | 1.05K shares |
|---|---|
| Open market or private sale | 13.4K shares |